Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by LithLoveron Jun 04, 2021 11:21am
102 Views
Post# 33329705

RE:Share Consolidation

RE:Share ConsolidationThe key is the upto as you have highlighted.  There is a specific reason to only request a 2:1.  This is the annual meeting so it gives the board the ability to execute over the next 12 months. 

Some would have you belive its a 10:1 and that it will happen tomorrow with all the doom and gloom talk.

With Shift Communicatiosn in our corner, the upcoming closing of Care Oncology, the recent increase in marketing and the start of Aristotle testing I believe the company feels they can achieve a much higher Sp.  On the last conference call Tripp mentions he expects Q2 revenue to be similar to Q1.  Factoring out warrant valuation which is just a paper loss the company had positive EBITDA and expect to continue with that.  There shouldn't be a big warrant valuation in Q2 so we could see a very positive quarter even on paper,

With a higher SP and having the ability to do a 2:1 consolidation (not higher) it wouldn't change shareholder holdings but could make the difference on an uplist.

Good things coming despite the constant bashing and short and distort campaign that is going on here.



  
Michael4444 wrote: I am surprised that I am not seeing more comments on this board, regarding the proposed share consolidation of UPTO 2 for 1.  As a fairly new investor, I have to wonder what mangement hopes to achieve.  At the current rate of decline, we would soon be back in this current price range!  I am hoping that my long range forecast, will turn out right, and not be whittled away by manipulation.


<< Previous
Bullboard Posts
Next >>